LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas

Conditions

• Bone Sarcoma
• Dedifferentiated Chondrosarcoma
• Giant Cell Tumor of Bone
• Malignancy in Giant Cell Tumor of Bone
• Malignant Solid Neoplasm
• Ovarian Carcinosarcoma
• Platinum-Resistant Ovarian Carcinoma
• Poorly Differentiated Thyroid Gland Carcinoma
• Recurrent Osteosarcoma
• Recurrent Ovarian Carcinoma
• Refractory Osteosarcoma
• Soft Tissue Sarcoma
• Thyroid Gland Anaplastic Carcinoma
• Thyroid Gland Squamous Cell Carcinoma
• Undifferentiated High Grade Pleomorphic Sarcoma of Bone
• Triple Negative Breast Cancer

Interventions

• BIOLOGICAL: Aldesleukin
• BIOLOGICAL: Autologous Tumor Infiltrating Lymphocytes LN-145
• BIOLOGICAL: Autologous Tumor Infiltrating Lymphocytes LN-145-S1
• DRUG: Cyclophosphamide
• DRUG: Fludarabine
• BIOLOGICAL: Ipilimumab
• BIOLOGICAL: Nivolumab
• OTHER: Quality-of-Life Assessment
• OTHER: Questionnaire Administration

Sponsor

M.D. Anderson Cancer Center

Collaborators

• [object Object]
• [object Object]